The stock is trading at about a 40% discount to its value. It has never traded that low. The problem is that the earnings forecasts have collapsed and are falling into negative ground. There is nothing to assign a value to when doing an analysis. The quality has slipped on the balance sheet. We should not lose site of the fact that they have some really interesting real estate holdings. He thinks IFRS accounting would apply a much higher value to their holdings. There could be a lot there from a net worth point of view.

It is like a number of faddish US stocks. It is overvalued, but loved. He would not endorse it. He thinks Trump could do all kinds of damage. This is off his buy list.

He is thinking this is dead money. The pillars that are driving this company aren’t. The remaining assets are the remaining contracts with governments. He thinks they should have been bought out. This thing is not working out. Mr. Chan has been dealt a hand he cannot win at.

The US administration are hitting drug pricing. It has hurt valuations. PFE-N has been relatively passed up. It has a 50% upside potential. It has technical support at $31. If this does not hold then get the heck out. GILD-Q is more beat up and looks very cheap.

He likes it. Finally conditions are coming together to let them break out into higher ground. They have good upside, and a lot of it.

(Top Pick Jan 26/16, Up 21.60%) He still likes it, but it is having a hard time getting anywhere. He would not buy it here anymore.

(Top Pick Jan 26/16, Up 36.76%) You just had to have it. It has done very well. It is trading at its net worth value so does not offer any more.